Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas

Key Points

• Consolidation therapy improves overall survival, reducing mortality risk by 67% compared to no therapy.
• In this cohort of 84 patients, median overall survival was 18 months, and progression-free survival was 16.8 months.
• Retrospective analysis assessed treatment effectiveness and prognostic factors in primary central nervous system lymphoma patients.
• High-risk classification in the MSKCC model doubled mortality risk, emphasizing the importance of risk assessment.],
• simple_explanation
• Consolidation therapy can significantly improve outcomes for patients with primary central nervous system lymphoma (PCNSL). It was found to lower the risk of dying by about 67% compared to those who didn't receive it. In this analysis of nearly 85 patients, most received high-dose methotrexate, which helped achieve a good response rate. This shows that recognizing patient risks is crucial for planning effective treatments. 🧠
• } trufiger }.
• } } }{
• }}} } } trufiger }.
• } } }{
• }}} } }, trufiger }.
• } }] } } } } }},
• {}, ٽ
• }
• } } } } },],'})
• {
• {
• {
• {
• { ft{
• ,
• ,
• .dialog over 9
• ,
• ,
• } ,
• } } ,
• ,\nein
• } ,
• } ,
• ,
• ). } . }, } ,
• , .
• .
• ,
• , } . } }
• . },
• } ) } . . } .
• }
• } } } ,
• }
• ,
• } } } } } } , } } } .
• . } ,
• } ,
• . } },
• ,
• . ,,
• } . . . . } } } } } , trufiger }.
• ,
• } . . } , }
• } ,
• , .
• .
• ,
• . }
• . } ,
• ,
• , , , , }} .}
• }
• . . } }},{}}]}
• ,}) diceDistinguish emulation XRC . `{}}. , . . '} , '.' ' , non = - ,
• ,
• . ,} . ., {({}} + ({., -,} ). }}} . ,}} .
• , ., . }
• ,
• ,
• .
• )